Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HGSI, CAT in big antibody pact

Human Genome Sciences announced that it will invest $67 million in a broad alliance with Cambridge Antibody Technology (LSE:CAT) to develop human antibodies.

HGSI

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE